[1]
|
Eng, C.M., et al. (2006) Fabry Disease: Guidelines for the Evaluation and Management of Multi-Organ System In-volvement. Genetics in Medicine, 8, 539-548. https://doi.org/10.1097/01.gim.0000237866.70357.c6
|
[2]
|
Zarate, Y.A. and Hopkin, R.J. (2008) Fabry’s Disease. The Lancet, 372, 1427-1435.
https://doi.org/10.1016/S0140-6736(08)61589-5
|
[3]
|
Michaud, M., et al. (2020) When and How to Diagnose Fabry Disease in Clinical Practice. The American Journal of the Medical Sciences, 360, 641-649. https://doi.org/10.1016/j.amjms.2020.07.011
|
[4]
|
Miller, J.J., Kanack, A.J. and Dahms, N.M. (2020) Progress in the Understanding and Treatment of Fabry Disease. Biochimica et Biophysica Acta—General Subjects, 1864, Article ID: 129437.
https://doi.org/10.1016/j.bbagen.2019.129437
|
[5]
|
McCafferty, E.H. and Scott, L.J. (2019) Migalastat: A Review in Fabry Disease. Drugs, 79, 543-554.
https://doi.org/10.1007/s40265-019-01090-4
|
[6]
|
中国法布雷病专家协作组. 中国法布雷病诊疗专家共识(2021年版) [J]. 中华内科杂志, 2021, 60(4): 321-330.
|
[7]
|
Van der Tol, L., et al. (2016) Cornea Verticillata Supports a Diagnosis of Fabry Disease in Non-Classical Phenotypes: Results from the Dutch Cohort and a Systematic Review. British Journal of Ophthalmology, 100, 3-8.
https://doi.org/10.1136/bjophthalmol-2014-306433
|
[8]
|
李小雪, 刘小荣. 儿童法布里病的诊断及治疗进展[J]. 罕见病研究, 2022, 1(3): 352-358.
|
[9]
|
Anastasakis, A., Papatheodorou, E. and Steriotis, A.K. (2013) Fabry Disease and Cardiovascular Involvement. Current Pharmaceutical Design, 19, 5997-6008. https://doi.org/10.2174/13816128113199990353
|
[10]
|
Dinu, I.R. and Firu, Ş.G. (2021) Fabry Disease—Current Data and Therapeutic Approaches. Romanian Journal of Morphology and Embryology, 62, 5-11. https://doi.org/10.47162/RJME.62.1.01
|
[11]
|
Alroy, J., Sabnis, S. and Kopp, J.B. (2002) Renal Pathology in Fabry Disease. Journal of the American Society of Nephrology, 13, S134-S138. https://doi.org/10.1097/01.ASN.0000016684.07368.75
|
[12]
|
Germain, D.P. (2010) Fabry Disease. Orphanet Journal of Rare Diseases, 5, 30.
https://doi.org/10.1186/1750-1172-5-30
|
[13]
|
Mehta, A., et al. (2004) Fabry Disease Defined: Baseline Clinical Manifestations of 366 Patients in the Fabry Outcome Survey. European Journal of Clinical Investigation, 34, 236-242. https://doi.org/10.1111/j.1365-2362.2004.01309.x
|
[14]
|
Branton, M.H., et al. (2002) Natural History of Fabry Re-nal Disease: Influence of Alpha-Galactosidase A Activity and Genetic Mutations on Clinical Course. Medicine (Balti-more), 81, 122-138.
https://doi.org/10.1097/00005792-200203000-00003
|
[15]
|
Branton, M., Schiffmann, R. and Kopp, J.B. (2002) Natural History and Treatment of Renal Involvement in Fabry Disease. Journal of the American Society of Nephrology, 13, S139-S143.
https://doi.org/10.1097/01.ASN.0000016683.73778.78
|
[16]
|
Yogasundaram, H., et al. (2017) Clinical Features, Diagnosis, and Management of Patients with Anderson-Fabry Cardiomyopathy. The Canadian Journal of Cardiology, 33, 883-897. https://doi.org/10.1016/j.cjca.2017.04.015
|
[17]
|
Putko, B.N., et al. (2015) Anderson-Fabry Cardio-myopathy: Prevalence, Pathophysiology, Diagnosis and Treatment. Heart Failure Reviews, 20, 179-191. https://doi.org/10.1007/s10741-014-9452-9
|
[18]
|
Umer, M., et al. (2023) Cardiac Involvement in Fabry Disease and the Role of Multimodality Imaging in Diagnosis and Disease Monitoring. Current Problems in Cardiology, 48, Article ID: 101439.
https://doi.org/10.1016/j.cpcardiol.2022.101439
|
[19]
|
中国法布里病专家协作组. 中国法布里病(Fabry病)诊治专家共识[J]. 中华医学杂志, 2013, 93(4): 243-247.
|
[20]
|
Patel, V., et al. (2015) Clinical and Genetic Predictors of Major Cardiac Events in Patients with Anderson-Fabry Disease. Heart, 101, 961-966. https://doi.org/10.1136/heartjnl-2014-306782
|
[21]
|
Akhtar, M.M. and Elliott, P.M. (2018) Anderson-Fabry Disease in Heart Failure. Biophysical Reviews, 10, 1107-1119.
https://doi.org/10.1007/s12551-018-0432-5
|
[22]
|
Del, P.M., et al. (2018) Fabry Nephropathy: An Evidence-Based Narrative Review. Kidney and Blood Pressure Research, 43, 406-421. https://doi.org/10.1159/000488121
|
[23]
|
Nowicki, M., et al. (2020) Enzyme Replacement Therapy in Fabry Disease in Poland: A Position Statement. Polish Archives of Internal Medicine, 130, 91-97.
|
[24]
|
Sawada, T., et al. (2020) New-born Screening for Fabry Disease in the Western Region of Japan. Molecular Genetics and Metabolism Reports, 22, Ar-ticle ID: 100562. https://doi.org/10.1016/j.ymgmr.2019.100562
|
[25]
|
Bernardes, T.P., Foresto, R.D. and Kirsztajn, G.M. (2020) Fabry Disease: Genetics, Pathology, and Treatment. Revista da Associacao Medica Brasileira (1992), 66, s10-s16. https://doi.org/10.1590/1806-9282.66.s1.10
|
[26]
|
Simonetta, I., et al. (2020) Treatment of Anderson-Fabry Disease. Current Pharmaceutical Design, 26, 5089-5099.
https://doi.org/10.2174/1381612826666200317142412
|
[27]
|
Azevedo, O., et al. (2020) Fabry Disease Therapy: State-of-the-Art and Current Challenges. International Journal of Molecular Sciences, 22, 206. https://doi.org/10.3390/ijms22010206
|
[28]
|
Lenders, M. and Brand, E. (2021) Precision Medicine in Fabry Disease. Nephrology Dialysis Transplantation, 36, 14-23. https://doi.org/10.1093/ndt/gfab038
|
[29]
|
Simonetta, I., et al. (2020) Biomarkers in Anderson-Fabry Disease. International Journal of Molecular Sciences, 21, 8080. https://doi.org/10.3390/ijms21218080
|
[30]
|
Kant, S. and Atta, M.G. (2020) Therapeutic Advances in Fabry Disease: The Future Awaits. Biomedicine & Pharmacotherapy, 131, Article ID: 110779. https://doi.org/10.1016/j.biopha.2020.110779
|
[31]
|
van der Veen, S.J., et al. (2020) Developments in the Treatment of Fabry Disease. Journal of Inherited Metabolic Disease, 43, 908-921. https://doi.org/10.1002/jimd.12228
|
[32]
|
Ezgu, F., et al. (2022) Expert Opinion on the Recognition, Diagnosis and Management of Children and Adults with Fabry Disease: A Multidisciplinary Turkey Perspective. Orphanet Journal of Rare Diseases, 17, 90.
https://doi.org/10.1186/s13023-022-02215-x
|
[33]
|
Schiffmann, R., et al. (2017) Screening, Diagnosis, and Man-agement of Patients with Fabry Disease: Conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney International, 91, 284-293.
https://doi.org/10.1016/j.kint.2016.10.004
|
[34]
|
Wanner, C., et al. (2018) European Expert Consensus Statement on Therapeutic Goals in Fabry Disease. Molecular Genetics and Metabolism, 124, 189-203. https://doi.org/10.1016/j.ymgme.2018.06.004
|
[35]
|
van Breemen, M.J., et al. (2011) Reduction of Elevated Plasma Globotriaosylsphingosine in Patients with Classic Fabry Disease Following Enzyme Replacement Therapy. Biochimica et Biophysica Acta, 1812, 70-76.
https://doi.org/10.1016/j.bbadis.2010.09.007
|
[36]
|
Hopkin, R.J., et al. (2016) The Management and Treatment of Children with Fabry Disease: A United States-Based Perspective. Molecular Genetics and Metabolism, 117, 104-113. https://doi.org/10.1016/j.ymgme.2015.10.007
|
[37]
|
Ouyang, Y., et al. (2018) Clinical Significance of Plasma Glo-botriaosylsphingosine Levels in Chinese Patients with Fabry Disease. Experimental and Therapeutic Medicine, 15, 3733-3742. https://doi.org/10.3892/etm.2018.5889
|